公开(公告)号：US08785140B2

公开(公告)日：2014-07-22

申请号：US11815420

申请日：2006-02-02

Applicant: Bruce M. Hall ,  Suzanne J. Hodgkinson

Inventor： Bruce M. Hall ,  Suzanne J. Hodgkinson

IPC: G01N33/50

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2033 ,  A61K38/208 ,  A61K38/217 ,  A61K39/001 ,  A61K2039/5158 ,  C07K16/244 ,  C07K2317/76 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2305 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/24 ,  G01N33/505 ,  G01N33/5094 ,  G01N2333/52 ,  G01N2333/54 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5434 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2333/70514 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2800/245 ,  A61K2300/00

Abstract: The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.

Abstract translation: 本发明涉及一种评估受试者是否包含已被激活到特异性抗原的CD4 +，CD25 + T细胞的方法。 该方法包括以下步骤：从受试者获得包含CD4 +，CD25 + T细胞的淋巴细胞样品，培养淋巴细胞样品的至少一部分，以促进已激活的CD4 +，CD25 + T细胞与特异性抗原的区别 从未激活到特异性抗原的那些CD4 +，CD25 + T细胞，然后确定是否存在活化于特异性抗原的CD4 +，CD25 + T细胞存在于样品中。 本发明还涉及在体外培养已被激活到特定抗原的CD4 +，CD25 + T细胞的方法和使用已经在体外培养的CD4 +，CD25 + T细胞增加受试者耐受性的方法。

公开(公告)号：US20180355318A1

公开(公告)日：2018-12-13

申请号：US15570191

申请日：2016-04-29

Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER

Inventor： Colleen Delaney ,  Stanley R. Riddell

IPC: C12N5/0789 ,  C12N5/0783 ,  A61K35/28 ,  G01N33/569 ,  C12N15/86 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C07K14/715

CPC classification number: C12N5/0647 ,  A61K35/28 ,  A61K39/0011 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7153 ,  C07K16/2803 ,  C07K2319/02 ,  C12N5/0646 ,  C12N15/86 ,  C12N2501/105 ,  C12N2501/113 ,  C12N2501/125 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2305 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2311 ,  C12N2501/26 ,  C12N2501/42 ,  C12N2501/599 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N2740/16043 ,  C12N2740/16045 ,  C12N2810/6081 ,  G01N33/56966

Abstract: Hematopoeitic stem/progenitor cells (HSPC) and/or non-T effector cells are modified to express an extracellular component including a tag cassette. The tag cassette can be used to activate, promote proliferation of, detect, enrich, isolate, track, deplete and/or eliminate modified cells. The cells can also be modified to express a binding domain.

公开(公告)号：US09404082B2

公开(公告)日：2016-08-02

申请号：US13990991

申请日：2011-12-02

Applicant: Tatsutoshi Nakahata ,  Kohichiro Tsuji ,  Feng Ma ,  Hirohisa Saito ,  Kenji Matsumoto

Inventor： Tatsutoshi Nakahata ,  Kohichiro Tsuji ,  Feng Ma ,  Hirohisa Saito ,  Kenji Matsumoto

IPC: C12N5/00 ,  C12N5/08 ,  C12Q1/02 ,  C12N5/0787 ,  C12N5/074 ,  G01N33/50

CPC classification number: C12N5/0642 ,  C12N5/0696 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/165 ,  C12N2501/20 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2305 ,  C12N2501/2306 ,  C12N2501/26 ,  C12N2502/02 ,  C12N2506/02 ,  C12N2506/45 ,  G01N33/5029 ,  G01N33/5047 ,  G01N33/505 ,  G01N2500/04 ,  G01N2500/10

Abstract: The present invention relates to a method for producing human eosinophils from human pluripotent stem cells. More specifically, the present invention provides a method for producing human eosinophils from human pluripotent stem cells, which method comprises the steps of: (1) co-culturing, in the presence of VEGF, human pluripotent stem cells with cells separated from the AGM region of a mammalian fetus; (2) performing suspension culture using a medium comprising IL-3, IL-6, Flt3 ligand, SCF, TPO and serum; (3) performing suspension culture using a medium comprising IL-3, SCF, GM-CSF and serum; and, optionally, (4) performing suspension culture using a medium comprising IL-3, IL-5 and serum.

Abstract translation: 本发明涉及从人多能干细胞生产人嗜酸性粒细胞的方法。 更具体地说，本发明提供从人多能干细胞生产人嗜酸性粒细胞的方法，该方法包括以下步骤：（1）在VEGF的存在下，将人多能干细胞与从AGM区域分离的细胞共培养 的哺乳动物胎儿; （2）使用包含IL-3，IL-6，Flt3配体，SCF，TPO和血清的培养基进行悬浮培养; （3）使用包含IL-3，SCF，GM-CSF和血清的培养基进行悬浮培养; 和（4）使用包含IL-3，IL-5和血清的培养基进行悬浮培养。

公开(公告)号：US11896614B2

公开(公告)日：2024-02-13

申请号：US15567156

申请日：2016-04-15

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： David M. Barrett ,  Felipe Bedoya ,  Saba Ghassemi ,  Carl H. June ,  Bruce L. Levine ,  Jan J. Melenhorst ,  Michael C. Milone ,  Daniel J. Powell, Jr. ,  Nathan Amar Singh ,  Zoe Zheng

IPC: A61K35/17 ,  C07K14/47 ,  C07K14/705 ,  A61K38/50 ,  A61K45/06 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/50 ,  A61K45/06 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C12N5/0636 ,  C12Y305/01001 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/2302 ,  C12N2501/2305 ,  C12N2501/2307 ,  C12N2501/2318 ,  A61K35/17 ,  A61K2300/00 ,  A61K38/50 ,  A61K2300/00

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

公开(公告)号：US11753624B2

公开(公告)日：2023-09-12

申请号：US15766657

申请日：2016-10-06

Applicant: Georgia Tech Research Corporation

Inventor： Krishnendu Roy ,  Kyung-Ho Roh

IPC: G01N33/53 ,  C12N5/0781 ,  A61K39/00

CPC classification number: C12N5/0635 ,  A61K39/00 ,  A61K2039/5158 ,  A61K2039/575 ,  C12N2501/231 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2305 ,  C12N2501/2321 ,  C12N2501/25 ,  C12N2501/52 ,  C12N2537/00

Abstract: The various embodiments of the disclosure relate generally to processes, methods, and systems for generating functional B cells ex vivo. It is particularly useful for ex vivo generation of antigen-specific germinal-center (GC) like B cells that are capable of efficient B cell expansion, immunoglobulin (Ig) class switching/class switching recombination (CSR), expression of germinal B cell phenotypes, antibody secretion, and somatic hypermutation (SHM) and resulting affinity maturation center phenotypes.

公开(公告)号：US20080279813A1

公开(公告)日：2008-11-13

申请号：US11815420

申请日：2006-02-02

Applicant: Bruce M. Hall ,  Suzanne J. Hodgkinson

Inventor： Bruce M. Hall ,  Suzanne J. Hodgkinson

IPC: A61K45/00 ,  C12Q1/04 ,  G01N33/53 ,  A61K38/21 ,  A61K39/00 ,  A61P37/00 ,  A61K31/70 ,  A61K35/12 ,  A61K39/395

CPC classification number: C12N5/0637 ,  A61K35/17 ,  A61K38/1793 ,  A61K38/20 ,  A61K38/2033 ,  A61K38/208 ,  A61K38/217 ,  A61K39/001 ,  A61K2039/5158 ,  C07K16/244 ,  C07K2317/76 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2305 ,  C12N2501/2312 ,  C12N2501/2323 ,  C12N2501/24 ,  G01N33/505 ,  G01N33/5094 ,  G01N2333/52 ,  G01N2333/54 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5434 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2333/70514 ,  G01N2333/70596 ,  G01N2333/715 ,  G01N2800/245 ,  A61K2300/00

Abstract: The invention relates to a method of assessing whether a subject comprises CD4+,CD25+ T cells that have been activated to a specific antigen. The method comprises the steps of obtaining from the subject a sample of lymphocytes comprising CD4+,CD25+ T cells, incubating at least one portion of the sample of lymphocytes so as to promote distinction of CD4+,CD25+ T cells that have been activated to the specific antigen from those CD4+,CD25+ T cells that have not been activated to the specific antigen, and thereafter determining whether CD4+,CD25+ T cells activated to the specific antigen are present in the sample. The invention further relates to methods of growing CD4+, CD25+ T cells that have been activated to a specific antigen in vitro and to methods of increasing tolerance in a subject using the CD4+, CD25+ T cells that have been grown in vitro.

Abstract translation: 本发明涉及一种评估受试者是否包含已被激活到特异性抗原的CD4 +，CD25 + T细胞的方法。 该方法包括以下步骤：从受试者获得包含CD4 +，CD25 + T细胞的淋巴细胞样品，培养淋巴细胞样品的至少一部分，以促进已激活的CD4 +，CD25 + T细胞与特异性抗原的区别 从未激活到特异性抗原的那些CD4 +，CD25 + T细胞，然后确定是否存在活化于特异性抗原的CD4 +，CD25 + T细胞存在于样品中。 本发明还涉及在体外培养已被激活到特定抗原的CD4 +，CD25 + T细胞的方法和使用已经在体外培养的CD4 +，CD25 + T细胞增加受试者耐受性的方法。

公开(公告)号：US20180133296A1

公开(公告)日：2018-05-17

申请号：US15567156

申请日：2016-04-15

Applicant: David Maxwell Barrett ,  Felipe Bedoya ,  Saba Ghassemi ,  Carl H. June ,  Bruce L. Levine ,  Jan J. Melenhorst ,  Michael C. Milone ,  Daniel J. Powell, Jr. ,  Nathan Amar Singh ,  Zoe Zheng

Inventor： David Maxwell Barrett ,  Felipe Bedoya ,  Saba Ghassemi ,  Carl H. June ,  Bruce L. Levine ,  Jan J. Melenhorst ,  Michael C. Milone ,  Daniel J. Powell, Jr. ,  Nathan Amar Singh ,  Zoe Zheng

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K38/50 ,  A61K45/06 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/4748 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C12N5/0636 ,  C12N2501/2302 ,  C12N2501/2305 ,  C12N2501/2307 ,  C12N2501/2318 ,  C12Y305/01001 ,  A61K2300/00

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

公开(公告)号：US20170042939A1

公开(公告)日：2017-02-16

申请号：US15231083

申请日：2016-08-08

Applicant: Tsinghua University

Inventor： Minghui ZHANG

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783 ,  C07K14/705

CPC classification number: A61K35/17 ,  A61K2035/124 ,  C12N5/0646 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/2304 ,  C12N2501/2305 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2309 ,  C12N2501/2312 ,  C12N2501/2315

Abstract: The disclosure discloses a kind of new NKT-like cell subpopulation, a therapeutical composition comprising the NKT-like cell subpopulation, and the medical use thereof. The disclosure also provides a preparation method of the NKT-like cell subpopulation. The disclosed NKT-like cell subpopulation has a strong antitumor effect, and can be adoptive transferred into a subject to treat the tumor in the subject after in vitro cultured and amplified.

Abstract translation: 本公开公开了一种新的NKT样细胞亚群，包含NKT样细胞亚群的治疗组合物及其医疗用途。 本公开还提供了NKT样细胞亚群的制备方法。 所公开的NKT样细胞亚群具有很强的抗肿瘤作用，并且可以在体外培养和扩增后将其过继转移到受试者中以治疗受试者的肿瘤。

公开(公告)号：US20050272152A1

公开(公告)日：2005-12-08

申请号：US11128950

申请日：2005-05-13

Applicant: Ruiling Xu ,  Andrea Liebmann-Vinson ,  Keith Deluca

Inventor： Ruiling Xu ,  Andrea Liebmann-Vinson ,  Keith Deluca

IPC: A61K45/00 ,  C12N5/00 ,  C12N5/0775 ,  C12N5/0789 ,  C12N5/08

CPC classification number: C12N5/0647 ,  C12N5/0663 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/42 ,  C12N2500/90 ,  C12N2501/10 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/13 ,  C12N2501/135 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/21 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/2303 ,  C12N2501/2305 ,  C12N2501/2306 ,  C12N2501/2311 ,  C12N2501/235 ,  C12N2501/26 ,  C12N2501/32 ,  C12N2501/39 ,  C12N2501/415 ,  C12N2501/58 ,  C12N2501/60 ,  C12N2501/70 ,  C12N2501/999 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/70

Abstract: The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.

Abstract translation: 本发明提供了扩增的CD34表达细胞和使用方法的群体。 具体实施方案提供用于生长这些细胞的限定的培养基和包含这些细胞的移植物。 本发明用于重组，修复和再生组织损伤的方法。

公开(公告)号：US20240043800A1

公开(公告)日：2024-02-08

申请号：US18264521

申请日：2022-02-04

Applicant: SUNGKWANG MEDICAL FOUNDATION

Inventor： Ji Yoon LEE ,  Ah Reum LEE ,  Jung Eun PARK

IPC: C12N5/078

CPC classification number: C12N5/0634 ,  C12N2501/165 ,  C12N2501/115 ,  C12N2501/145 ,  C12N2501/14 ,  C12N2501/105 ,  C12N2501/125 ,  C12N2501/2305 ,  C12N2501/2307 ,  C12N2501/155 ,  C12N2501/2306 ,  C12N2501/2315 ,  C12N2500/38 ,  C12N2501/22 ,  C12N2501/998

Abstract: Provided is a method of differentiating a pluripotent stem cell-derived hemogenic endothelial cell into a lymphoid lineage blood cell, enabling a hemogenic endothelial cell to be cultured for a long period of time so as to be induced into a lymphoid lineage blood cell, thereby facilitating induction of generation of immune cells such as T cells, B cells, and NK cells.